All News

JAK Janus

JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?

d Aurelie Najm, MD, PhD

Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases. 

Read Article
There are 494K PCPs in the USA, While up to 1/3 will "refill" DMARDs, only 6-9% are confident or knowledgeable in "initiating" DMARD therapy in #RA. GIGANTIC NEED FOR PCP education in MSK & Rheum Dz https://t.co/VjgWWDt3nX https://t.co/dTRXxsrzG5

Links:

Dr. John Cush RheumNow ( View Tweet)

There are 494K PCPs in the USA, While up to 1/3 will "refill" DMARDs, only 6-9% are confident or knowledgeable in "initiating" DMARD therapy in #RA. GIGANTIC NEED FOR PCP education in MSK & Rheum Dz https://t.co/VjgWWDt3nX https://t.co/dTRXxsrzG5

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of interferon (IFN) gene signature (IGS) finds IGS elevated in half of early RA pts; high IGS portends higher DAS28, fewer EULAR good resp & higher IFN-α; the latter assoc w/ epigentic changes, more lymphoctye activation. IFN-α as a biomarker? https://t.co/BHC98OR30A https://t.co/SRE7KVaoha

Links:

Dr. John Cush RheumNow ( View Tweet)
GLORIA Study Pred vs PBO in >65yrs RA x 2 years. 451 Pts & DAS28 4.5. 79% on DMARDs (14% biologics) Upside: Lower DAS28 -0.37 & less Xray progression -1.7 Sharp units Downside: 24% more AE (mild infxns), signif.small lowering of lumbar BMD -1% You Decide https://t.co/RRq0WcFsXz https://t.co/xLxjPPSMhh

Links:

Dr. John Cush RheumNow ( View Tweet)
CV risk factors not equal when considering magnitude of risk What can we learn from Oral Surveillance? The Oral Surveillance trial has almost become a household word for rheumatologists. https://t.co/LHZTVZh4AK https://t.co/2SlxrG7UpQ

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

EULAR 2022 Top 10 Abstracts (6.10.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the top abstracts from EULAR 2022  As chosen by me with the  aid of the RheumNow EULAR faculty.

Read Article
heart.jpg (keep)

CV risk factors not equal when considering magnitude of risk

d Janet Pope, MD, MPH, FRCPC

What can we learn from Oral Surveillance?



The Oral Surveillance trial has almost become a household word for rheumatologists.

Read Article
Can we stop RA before it happens? Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent RA occurring in at-risk individuals. https://t.co/vU4tRr7UJh https://t.co/cikU9pwaiT

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling https://t.co/Lp25lP6ZZY https://t.co/wd5GCbaCLR

Links:

Dr. John Cush RheumNow ( View Tweet)
Yes No

Can we stop RA before it happens?

d David Liew, FRACP

Rheumatologists have long hoped and wondered whether the right type of early intervention could prevent rheumatoid arthritis occurring in at-risk individuals.

Read Article
Video: Residual Pain in RA Dr. Maxime Dougados discusses OP0052 at #EULAR2022. https://t.co/gu1Svegss8 https://t.co/G1rRizG9gW

Links:

Dr. John Cush RheumNow ( View Tweet)
Canadian study of 50,883 RA pts shows only 58% saw a rheumatologist yearly for 5 yrs. If >65 yrs, Rheum care assoc w/ DMARD use in 82%; but was only 31% if not under Rheum care. Worse rheum retention with age >81, male, lower SES, older Rheums https://t.co/xUxWaksgsE

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA approved another rituximab biosimilar, rituximab-arrx (Riabni) (from Amgen), for use w/ MTX in active RA. Riabni is not currently approved for B-cell NHL, B-cell leukemia, MPA, or GPA. or pemphigus vulgaris (RTX is an orphan drug) https://t.co/Htk0xBx63X https://t.co/ep1L3YO9hl

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Major Consequences of Depression In RA https://t.co/aVzIHDiRZ4 https://t.co/86RLXJKb64

Links:

Dr. John Cush RheumNow ( View Tweet)
cannabis,weed,marijuana

Is Pain Control by Cannabis an Option?

d Jack Cush, MD

An Annals of Internal Medicine review has shown that clinical trials and cohort studies of cannabinoids use for chronic pain may be associated with short-term improvements in chronic pain but come with an increased risk for dizziness and sedation.

Read Article
VIDEO: No Glory in GLORIA Dr. Richard Conway discusses abstract OP0263 presented at #EULAR2022. https://t.co/tlsTPztYqY https://t.co/5dOma69vLZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Let’s Talk about Sex and Autoimmune Disease Dr. Eric Dein discusses abstract OP0139 presented at #EULAR2022. https://t.co/fNcIbykFqL https://t.co/6UaH5DIc51

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Demystifying Synovial Tissue Biology Dr. Aurelie Najm ( @AurelieRheumo) discusses abstracts OP0084 and OP0085 presented at #EULAR2022. https://t.co/LNfFmxiE8O https://t.co/aiLvdtxYRB

Links:

Dr. John Cush RheumNow ( View Tweet)
VIDEO: Golden Window in Pre-RA Dr. Richard Conway ( @RichardPAConway) discusses abstract OP0070 presented at #EULAR2022. https://t.co/VoVo4TTgvO https://t.co/7NrZqJlwjo

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.